Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Development"

3125 News Found

Sai Life Sciences, Agility Life Sciences, and Centrix Pharma Solutions launch Integrated CMC Partnership to accelerate drug development
News | October 08, 2025

Sai Life Sciences, Agility Life Sciences, and Centrix Pharma Solutions launch Integrated CMC Partnership to accelerate drug development

The collaboration combines the extensive CMC expertise of Sai Life Sciences in API development, Agility Life Sciences in formulation development, and Centrix Pharma Solutions in drug product development and clinical manufacturing


Merck & Siemens join forces to accelerate AI drug discovery and development
Digitisation | September 24, 2025

Merck & Siemens join forces to accelerate AI drug discovery and development

Merck and Siemens signed new MoU extending their strategic partnership to accelerate digital transformation in the life science industry


Gilead Sciences breaks ground on new manufacturing and technical development site in US
News | September 09, 2025

Gilead Sciences breaks ground on new manufacturing and technical development site in US

New Bay Area building marks significant progress as part of $32 billion US investment projected to create $43 billion in economic value


Quotient Sciences and CPI join forces to accelerate RNA drug development
News | September 05, 2025

Quotient Sciences and CPI join forces to accelerate RNA drug development

The partnership will create a first-of-its-kind, fully integrated offering for the development of mRNA drug products


Bristol Myers Squibb appoints Cristian Massacesi as EVP, Chief Medical Officer, and Head of Development
People | July 31, 2025

Bristol Myers Squibb appoints Cristian Massacesi as EVP, Chief Medical Officer, and Head of Development

He most recently served as Chief Medical Officer of AstraZeneca and Alexion


argenx advances clinical development of agonist antibody for myasthenic syndromes
News | July 04, 2025

argenx advances clinical development of agonist antibody for myasthenic syndromes

ARGX-119 is the sixth molecule developed through our Immunology Innovation Program to show proof-of-concept


Roche to advance prasinezumab into Phase III development for early-stage Parkinson's disease
News | June 16, 2025

Roche to advance prasinezumab into Phase III development for early-stage Parkinson's disease

Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson’s disease progression


Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development
News | June 16, 2025

Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development

The decision to advance subcutaneous and oral amycretin into phase 3 is based on feedback received from regulatory authorities